April 19th 2024
"We look forward to announcing initial efficacy and safety data from the study, which we expect will be at the end of this quarter," says Salim Yazji, MD.
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
How the Experts Treat NMIBC During a BCG Shortage—Integrating Recent Approvals and Investigational Therapies
View More
Staying Abreast of the Prostate Cancer Treatment Paradigm From Risk Stratification to Adaptive Sequencing Strategies
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Medical Crossfire®: How Will Emerging Data Inform Treatment Planning for Patients With Prostate Cancer in the Community?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Scheduling and Administering Leuprolide: Key Challenges and Practical Solutions
August 18th 2023Key opinion leaders briefly review the key challenges in scheduling leuprolide administration for patients with advanced prostate cancer, including treatment delays, disease breakthrough, and insurance reimbursement, and share solutions to overcome these challenges.
Prostate cancer treatment deintensification: When less is more
August 16th 2023"Despite challenges, ongoing research and advancements in risk stratification, imaging techniques, and targeted therapies are paving the way for personalized and precision medicine approaches in prostate cancer management," writes Michael S. Cookson, MD, MMHC, FACS.
Racial concordance associated with trust of online prostate cancer videos among Black Americans
July 31st 2023“Increasing the representation of physicians (or actors) who appear concordant with the target audience may be an important tool for more effective health communication strategies to mitigate health disparities," the authors write.
Cross-Specialty Communications in Prostate Cancer
July 31st 2023In the second installment of this series, Ryan A. Hankins, MD, and Sean P. Collins, MD, PhD, provide insights on the multidisciplinary approach to treating patients with prostate cancer and discuss the roles of urologists and radiation oncologists.
Dr. Spratt on the potential use of an AI biomarker in treatment decision making for prostate cancer
July 28th 2023“The real immediate use case is that this biomarker can be an adjunct, or it can be something to assist in making the shared decision making with patients [with prostate cancer],” says Daniel E. Spratt, MD.